The company posted a multifold jump per cent in consolidated net profit to Rs 230 crore as compared to Rs 46 crore a year ago ...

Ovarian cancer continues to pose a significant challenge in the medical field, remaining one of the leading causes of death ...

GlaxoSmithKline Pharmaceuticals shares surged 20% to ₹2,421.30 after a strong Q3FY25 performance, reporting a 400% rise in ...

LONDON - On Wednesday, GlaxoSmithKline plc (NYSE: NYSE:GSK ... performance was driven by continued growth in its Specialty Medicines segment, which saw sales increase 17% year-over-year to ...

Their prescription medicines range across therapeutic ... This follows a global transaction between GlaxoSmithKline plc, UK (GSK) and Novartis AG, Switzerland (Novartis) which was completed ...

It also provides medicines for HIV, oncology ... The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in ...

Please note the value of investments can go down as well as up so you may get back less than you invested. This information is not a personal recommendation for any particular investment. If you are ...

While Neimeth International Pharmaceuticals and Morrison Industries Plc reported a loss in their profit during the period. In 2023, GlaxoSmithKline (GSK ... The cost of drugs in Africa’s fourth ...

Azoles, a class of antifungal drugs, continue to dominate due to their broad-spectrum ... Arcadia Consumer Healthcare Inc., Astellas Pharma Inc, GlaxoSmithKline Plc, Merck & Co. Inc., Novartis A.G, ...